

Publishable Summary

This quarterly report provides an overview of the project progress within the AMYPAD Prognostic and Natural History Study (WP4), with a focus on the period from October to December 2021.

In Q4 2021, COVID-19 did not directly affect sites, however during this period the recruitment and scan activity within the PNHS has been affected by the Christmas holiday during which some sites fully stopped their activities or continued at a slower pace. In addition, more and more sites finished the recruitment and scanning of their participants and some additional issues across the sites affected the recruitment and scan activity. As a result, the recruitment rates stagnated and the scanning rates decreased compared to Q3 2021. Only the number of scans (69) in October 2021 showed the same trend as the number of scans per month in Q2 2021 (quarter with the highest number of scans since start of AMYPAD PNHS). Despite this in Q4 2021 more sites were able to close the gap between consented and scanned which was mainly caused by the COVID-19 crisis and more sites started with the EPAD FU scans.

In total, at the end of Q4 2021, AMYPAD PNHS had 1181 participants consented of which 1220 have already received a PET scan. Moving forward, in Q1 2022 the recruitment and scanning rates will stagnate/decrease as we are slowly approaching the end of the study and more and more sites are (almost) finished with the recruitment and/or scanning of their participants.

For more information: info@amypad.org

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.



innovative
medicines
initiative